CLSN - Celsion Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Celsion Corporation

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609-896-9100
http://www.celsion.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael H. TardugnoExec. Chairman, Pres & CEO539.25kN/A1951
Mr. Jeffrey W. Church CPA, CPACFO, Sr. VP of Corp. Strategy & Investor Relations354.04kN/A1957
Dr. Khursheed AnwerExec. VP & Chief Scientific Officer315.32kN/A1960
Dr. Nicholas BorysVP & Chief Medical Officer381.83kN/A1959
Mr. Timothy J. TumminelloChief Accounting Officer & ControllerN/AN/A1958
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Corporate Governance

Celsion Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.